[{"id":"95fe996a-08c8-4bbd-9a80-6d6d99bc679d","acronym":"REFRaME-O1","url":"https://clinicaltrials.gov/study/NCT05870748","created_at":"2023-05-23T16:06:11.980Z","updated_at":"2024-07-02T16:35:08.676Z","phase":"Phase 2/3","brief_title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","source_id_and_acronym":"NCT05870748 - REFRaME-O1","lead_sponsor":"Sutro Biopharma, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression • FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-19"}]